Latest Earnings Analysis

• J. Jill (JILL) Q4 2025: Tariff Costs Double to $15M, Forcing Margin Reset and Strategic Rebuild
  March 31, 2026 · JILL
• TE (TE) Q4 2025: $322M Capital Raise Unlocks G2 Solar Fab Buildout Amid U.S. Supply Chain Shift
  March 31, 2026 · TE
• MNSO Q4 2025: Overseas Revenue Climbs 31% as Multi-IP Strategy Accelerates Global Store Expansion
  March 31, 2026 · MNSO
• Jiayin Group (JFIN) Q4 2025: Overseas Loan Volume Jumps 187%, Offsetting Domestic Contraction
  March 31, 2026 · JFIN
• Diomedica (DMAC) Q4 2025: R&D Spend Climbs 29% as Preeclampsia and Stroke Pipelines Advance
  March 31, 2026 · DMAC
• AIRO (AIRO) Q4 2025: $150M Drone Backlog Anchors 2026 Defense Growth Ambitions
  March 31, 2026 · AIRO
• Lantern Pharma (LTRN) Q4 2025: R&D Spend Down 29% as AI Pipeline Hits Clinical Inflection
  March 31, 2026 · LTRN
• Progress Software (PRGS) Q1 2026: Operating Margin Surges to 41% as AI and ShareFile Drive Cash Flow
  March 31, 2026 · PRGS
• Fathom Holdings (FTHM) Q4 2025: Edge Plan Lifts Gross Profit per Transaction 116%, Reshaping Brokerage Economics
  March 31, 2026 · FTHM
• CBAT Q4 2025: Battery Revenue Jumps 36% as Next-Gen Ramp Drives Margin Reset
  March 31, 2026 · CBAT
• RenovoRx (RNXT) Q4 2025: Active Site Pipeline Triples, Anchoring $3-4M Revenue Target
  March 31, 2026 · RNXT
• PHR Q4 2026: Network Solutions Revenue Cut Drives $35M Guidance Reset, Margin Holds on AI Efficiencies
  March 31, 2026 · PHR
• CVV Q4 2025: SDC Divestiture Nets $16.9M as Backlog Shrinks 66%
  March 31, 2026 · CVV
• PDS Biotech (PDSB) Q4 2025: Phase III Protocol Shift Cuts Trial Duration by 1 Year
  March 31, 2026 · PDSB
• Spruce Power (SPRU) Q4 2025: O&M Expense Down 64% as Platform Efficiency Accelerates
  March 31, 2026 · SPRU
• HireQuest (HQI) Q4 2025: MRI Divestiture Cuts $2M Royalty, Refocuses on Franchise Core
  March 31, 2026 · HQI
• InVenture (INV) Q4 2025: G&A Down 61% as Platform Shifts to Self-Funding, $50M Bookings Signal Inflection
  March 31, 2026 · INV
• ImmuneBio (INMB) Q4 2025: Cordstrom Heads for 2026 Regulatory Filings as R&D Spend Drops 38%
  March 31, 2026 · INMB
• Intellinetics (INLX) Q4 2025: SaaS Revenue Climbs 8.4% as Professional Services Lags Recovery
  March 31, 2026 · INLX
• ZSPC Q4 2025: Software and Services Mix Hits 57%, Driving 8.4 Point Margin Expansion
  March 31, 2026 · ZSPC
• Virgin Galactic (SPCE) Q4 2025: $750K Ticket Pricing and 26% Cost Cut Set Stage for Commercial Launch
  March 31, 2026 · SPCE
• Resolve AI (RZLV) Q4 2025: ARR Surges to $232M, Unlocking Agentic Commerce Scale
  March 30, 2026 · RZLV
• Bicara Therapeutics (BCAX) Q4 2025: 129 Global Sites and $414.8M Cash Position Fuel Fisera Launch Trajectory
  March 30, 2026 · BCAX
• SKYX Q4 2025: Plug-and-Play Smart Home Revenue Set to Surpass 10% Amid Builder and Retail Expansion
  March 30, 2026 · SKYX
• Americas Gold and Silver (USAS) Q4 2025: Silver Output Jumps 52% as Galena Upgrades Drive Production Momentum
  March 30, 2026 · USAS
• Numora Therapeutics (NMRA) Q4 2025: NMRA 215 Clinic Entry Delayed to 2027 After Toxicology Setback
  March 30, 2026 · NMRA
• Braskem (BAK) Q4 2025: Leverage Climbs to 14.7x as Downcycle Pressures Cash and Strategy
  March 28, 2026 · BAK
• P3 Health Partners (PIII) Q4 2025: $170M EBITDA Turnaround Anchored by Contracting and Cost Reset
  March 28, 2026 · PIII
• Laird Superfood (LSF) Q4 2025: Wholesale Channel Surges 44% as Navitas Acquisition Doubles Platform Scale
  March 28, 2026 · LSF
• Kopin (KOPN) Q4 2025: $37M Backlog Sets Stage for Defense-Driven Recovery
  March 27, 2026 · KOPN
• Southland (SLND) Q4 2025: $226M Surety Infusion Reshapes Capital Structure Amid $193M Legacy Loss
  March 27, 2026 · SLND
• Autolist (AUTL) Q4 2025: 92% Real-World Remission Validates $120M+ Guidance and Expansion Ambitions
  March 27, 2026 · AUTL
• Huize (HUIZ) FY25: AI-Driven Self-Service Up 50%, Offsetting Margin Drag from International Mix
  March 27, 2026 · HUIZ
• Nortec Systems (NSYS) Q4 2025: Backlog Climbs 17.4% as Restructuring Lifts Margins
  March 27, 2026 · NSYS
• Carnival (CCL) Q1 2026: $2.5B Buyback Signals Capital Return Shift Amid $500M Fuel Headwind
  March 27, 2026 · CCL
• 51Talk (COE) Q4 2025: Operating Expenses Surge 104% as Global Expansion Drives Top-Line Growth
  March 27, 2026 · COE
• Allegiance (TMC) Q4 2025: Backlog Surges 49%, Extending Data Center Visibility to 2029
  March 27, 2026 · TMC
• Carnival (CUK) Q1 2026: $2.5B Buyback, 16% ROIC Target Anchor Propel Plan
  March 27, 2026 · CUK
• Huize (HUIZ) FY25: International Revenue Surges 84%, Margin Mix Shifts as AI Drives Platform Scale
  March 27, 2026 · HUIZ
• Humacyte (HUMA) Q4 2025: VAC Approval Rate Tops 70% as Symbeth Adoption Broadens
  March 27, 2026 · HUMA
• IMDX Q4 2025: 28 Centers Join Registry as FDA Submission Drives Commercial Ramp
  March 27, 2026 · IMDX
• XOS (XOS) Q4 2025: Free Cash Flow Swings $54M as Hub and Powertrain Mix Accelerates
  March 27, 2026 · XOS
• Vertra (VTSI) Q4 2025: $25.6M Backlog Anchors Recovery as Federal Funding Thaws
  March 27, 2026 · VTSI
• Capsovision (CV) Q4 2025: Hospital System Customers Surge 87% as AI Pipeline Accelerates
  March 27, 2026 · CV
• Argan (AGX) Q4 2026: $2.5B in New Contracts Fuels Record Backlog Amid Grid Demand Surge
  March 27, 2026 · AGX
• Oxford Industries (OXM) Q4 2025: $50M Tariff Headwind Drives Margin Reset, DTC Mix Powers Tommy Bahama Momentum
  March 27, 2026 · OXM
• Endeavour Silver (EXK) Q4 2025: Silver Equivalent Output Jumps 146% on Terranera and Colpa Integration
  March 27, 2026 · EXK
• Alpha Cognition (ACOG) Q4 2025: Zunvel Prescriber Base Expands 50% as Repeat Orders Anchor Growth Trajectory
  March 27, 2026 · ACOG
• WRAP (WRAP) Q4 2025: Subscription Revenue Jumps 85% as Platform Shift Drives Pipeline Surge
  March 27, 2026 · WRAP
• DARE (DARE) Q4 2025: $13.9M Grant Offset Powers Pipeline, Commercial Launches Set for 2026
  March 27, 2026 · DARE